Sort   by:  
 Page size 
MetabolomicsIntra-tumoral microbial community profiling and associated metabolites alterations of TNBC

Triple-negative breast cancer (TNBC) presents significant challenges to female

health owing to the lack of therapeutic targets and its poor prognosis. In recent

years, in the field of molecular pathology, there has been a growing focus on the

role of intra-tumoral microbial comm...

2025-10-12 | MTBLS13119 | MetaboLights
GenomicsLigand-dependent genomic function of glucocorticoid receptor in triple-negative breast cancer
Glucocorticoids (GC) have been widely used as coadjuvants in the treatment of solid tumors, but GC treatment may be associated with poor pharmacotherapeutic response and/or prognosis. The genomic action of GC in these tumors is largely unknown. Here we find that dexamethasone (Dex, a synthetic GC) r...
ORGANISM(S): Homo sapiens 
2015-09-18 | E-GEOD-56022 | biostudies-arrayexpress
TranscriptomicsHuman TNBC Cells 48h Treatment with OTSSP167 MELK Inhibitor vs. DMSO Control
Microarray comparing TNBC cells treated for 48 hours with OTSSp167 MELK Inhibitor and control (DMSO) Two-condition arrays: MDA-MB-231 cells were treated with either 4.5nM OTSSP167 MELK Inhibitor or 0.045% DMSO for 48h. Two biological replicates, one per array, with a dye swap (technical replicate).
ORGANISM(S): Homo sapiens 
2017-05-01 | E-GEOD-68652 | biostudies-arrayexpress
TranscriptomicsHuman TNBC Cells 72h Treatment with 45nM OTSSP167 MELK Inhibitor vs. DMSO Control
Microarray comparing TNBC cells treated for 72 hours with OTSSP167 MELK Inhibitor and control (DMSO) Two-condition arrays: MDA-MB-231 cells were treated with either 45nM OTSSP167 MELK Inhibitor or 0.045% DMSO for 72h. Two biological replicates, one per array, with a dye swap (technical replicate).
ORGANISM(S): Homo sapiens 
2017-05-01 | E-GEOD-68692 | biostudies-arrayexpress
TranscriptomicsHuman TNBC Cells 72h Treatment with 4.5nM OTSSP167 MELK Inhibitor vs. DMSO Control
Microarray comparing TNBC cells treated for 72 hours with OTSSP167 MELK Inhibitor and control (DMSO) Two-condition arrays: MDA-MB-231 cells were treated with either 4.5nM OTSSP167 MELK Inhibitor or 0.045% DMSO for 72h. Two biological replicates, one per array, with a dye swap (technical replicate).
ORGANISM(S): Homo sapiens 
2017-05-01 | E-GEOD-68691 | biostudies-arrayexpress
TranscriptomicsHuman TNBC Cells 72h Treatment with 4.5nM OTSSP167 MELK Inhibitor vs. DMSO Control (SUM159)
Microarray comparing TNBC cells treated for 72 hours with OTSSP167 MELK Inhibitor and control (DMSO) Two-condition arrays: SUM159 cells were treated with either 4.5nM OTSSP167 MELK Inhibitor or 0.045% DMSO for 72h. Two biological replicates, one per array, with a dye swap (technical replicate).
ORGANISM(S): Homo sapiens 
2017-05-01 | E-GEOD-71026 | biostudies-arrayexpress
TranscriptomicsHuman TNBC Cells 72h Treatment with 45nM OTSSP167 MELK Inhibitor vs. DMSO Control (SUM159)
Microarray comparing TNBC cells treated for 72 hours with OTSSP167 MELK Inhibitor and control (DMSO) Two-condition arrays: SUM159 cells were treated with either 45nM OTSSP167 MELK Inhibitor or 0.045% DMSO for 72h. Two biological replicates, one per array, with a dye swap (technical replicate).
ORGANISM(S): Homo sapiens 
2017-05-01 | E-GEOD-71027 | biostudies-arrayexpress
MetabolomicsVesicle-mediated mitochondrial clearance presents an actionable metabolic vulnerability in triple-negative breast cancer

Selective autophagy of mitochondria is known to promote survival and progression of cancer cells in various malignancies, including triple-negative breast cancer (TNBC). Here, we investigate the essential metabolic adaptations that support mitochondrial quality control in cancer cells with the ai...

2025-09-30 | MTBLS13037 | MetaboLights
TranscriptomicsGene expression profiling of triple negative breast cancer, normal ductal cells, and normal tissues
To identify novel molecular targets for triple negative breast cancer (TNBC), we have employed whole genome microarray expression profiling. We purified 30 surgically resected breast cancer tissue diagnosed triple negative by means of immunohistochemical staining and 13 normal mammary ductal cells...
ORGANISM(S): Homo sapiens 
2012-12-21 | E-GEOD-38959 | biostudies-arrayexpress
TranscriptomicsPredicting Response and Survival in Chemotherapy-Treated Triple-Negative Breast Cancer
Gene expression data of pre-treatment samples of GEICAM2006-03 TNBC trial Patients were randomized to carboplatin or no carboplatin in the neoadjuvant setting In the study presented here, a well-defined cohort of 69 breast samples were used to acquire expression profiles of a total of 543 unique gen...
ORGANISM(S): Homo sapiens 
2014-08-11 | E-GEOD-58479 | biostudies-arrayexpress
Sort   by:  
 Page size